Treatment of Clostridium difficile-Associated Diarrhea and Colitis

  • D. N. Gerding
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 250)


Treatment of Clostridium difficile diarrhea is well established and has not changed markedly over the past two decades (Peterson and Gerding 1990). The major shift in therapeutic choice has been toward greater use of metronidazolc rather than vancomycin because of increasing concern about vancomycin resistance in organisms such as the enterococcus (HICPAC 1995). However, this should not be interpreted to mean that improvements in therapy are not needed. There continue to be major deficiencies related to high recurrence rates following treatment, and there are no clearly effective treatments for patients with complications such as ileus, toxic megacolon, and perforation. There is increasing interest in biotherapeutic or probiotic approaches to the management of C. difficile disease, both for prevention and treatment (Elmer et al. 1996). Currently, evidence of efficacy for biologic agents is available only for the yeast Saccharonivccs houlardii as an adjunctive therapy for the treatment of recurrent C. difficile diarrhea (McFarland et al. 1994).


Fusidic Acid Pseudomembranous Colitis Toxic Megacolon Vancomycin Resistance Oral Vancomycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Altaic SS, Meyer I’, Dryja D(1994) Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J (’lin Microbioi 13251 53Google Scholar
  2. Arabi Y, Dimock F, Burdon OW. Alexander-Willliams J, Keighley MRB (1979) Influence of neomycin and metronidazole on colonic microllora of volunteers. J Antimicrob Chemother 5:531 537Google Scholar
  3. Arrow SA, Croese L. Bowman RA, Riley TV (1994) Evaluation of three commercial enzyme immuno-assay kits for detecting faecal Clostridium r/i/ficile toxins..1 Clin Pathol 47: 954 956Google Scholar
  4. Bacon AL, McGrath S, Fekety R, Holloway W.I (1991) In vitro synergy studies with Clostridium difficile. Antimicrob Agents Chemother 35: 582–583PubMedCrossRefGoogle Scholar
  5. Bannatyne R. Jackowski J (1987) Susceptibility of Closirirlium difficile to metronidazole. its bioactivc metabolites and tinidazole. Fur J (’lin Microbiol 6: 505Google Scholar
  6. Bartlett JG (1992) The 10 most common questions about Clostridium difficilessociated diarrhea colitis. Infect Dis Clin Pract 1: 254–259CrossRefGoogle Scholar
  7. Bassetti S. Frei R. Zimmerli W (1998) i ungemia with SaccClostridium difficile treatment with Sotc/iwm,nrrs houlardii. Am.1 Med 105: 71 72Google Scholar
  8. Biavasco F, Manso E, Varaldo PE (1991) In vitro activities of ramoplanin and four glycopeptide anti-biotics against clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 35: 195 197Google Scholar
  9. Bolton RP, Culshaw MA (1986) Fecal metronidazole concentrations during oral and intravenous therapy for antibiotic-associated colitis due to Clostridium difficile. Gut 27: 1169–1172PubMedCrossRefGoogle Scholar
  10. Bradbury AW, Barrett S (1997) Surgical aspects of Clostridium difficile colitis. Br J Surg 84: 150–159PubMedCrossRefGoogle Scholar
  11. Buggy BP, Fekety R, Silva J Jr (1987) Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 9: 155–159PubMedCrossRefGoogle Scholar
  12. Burdon DW, Brown DJ, Youngs DJ, Arabi Y, Shinagawa N, Alexander-Williams J, Keighley MRB (1979) Antibiotic susceptibility of Clostridium J Antimicrob Chemother 5: 307–310CrossRefGoogle Scholar
  13. Chatila W, Manthous CA (1995) Clostridium difficile causing sepsis and an acute abdomen in critically ill patients. C’rit Care Med 23: 1146–1150Google Scholar
  14. deLalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A (1992) Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 36: 2192–2196CrossRefGoogle Scholar
  15. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R (1986) Oral hacitracin versus vancomycin therapy for Clostridium difficile-induced diarrhea: A randomized, double-blind trial. Arch Intern Med 146: 1101–1104Google Scholar
  16. Elmer GW, Surawicz CM, McFarland LV (1996) Biotherapeutic Agents. J Amer Med Assoc 275:870–876 Fekety R (1997) Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroent 92: 739–750Google Scholar
  17. Fekety R, Shah AB (1993) Diagnosis and treatment of Clostridium difficile colitis. J Amer Med Assoc 269: 71–75CrossRefGoogle Scholar
  18. Fekety R, Silva J, Kauffman C, Buggy B, Decry G (1989) Treatment of antibiotic-associated C losiridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 86: 15 19Google Scholar
  19. Finegold SM, George WL (1988) Therapy directed against Clostridium difficile and its toxins: complications of therapy. In: Rolfe RD, George WL (eds) Clostridium difficile: its role in intestinal disease. Academic Press, New York, pp 341–357Google Scholar
  20. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr (1995) Clostridium difficile-associated diarrhea and colitis. Infect Cont Hosp Epidemiol 16: 459–477Google Scholar
  21. Gerding DN, Olson MM, Peterson LR, Teasley DG, Gehhard RL, Schwartz ML, Lee JT Jr (1986) C/osiridiuni diffici/e-associated diarrhea and colitis in adults: A prospective case-controlled epidemiologic study. Arch Intern Med 146: 95–100Google Scholar
  22. Gorbach SL (1996) Clostridium difficile-associated diarrhea. Infect Dis Clin Practice 5:84Google Scholar
  23. Gorbach SL, Chang T-W, Goldin B (1987) Successful treatment of relapsing Clostridium difficile colitis with lactobacillus 0G. Lancet ii: 1519Google Scholar
  24. Grundfest-Broniatowski S, Quader M, Alexander F, Walsh RM, Lavery I, Milsom J (1996) Clostridium difficile colitis in the critically ill. Dis Colon Rectum 39: 619–623Google Scholar
  25. Guzman R, Kirkpatrick J, Forward K, Lim F (1988) Failure of parenteral metronidazole in the treatment of pseudomembranous colitis. J Infect Dis 158: 1146PubMedCrossRefGoogle Scholar
  26. Hoverstad T, Carlstedt-Duke B, Lingaas E, Miltvedt T, Norio KE, Saxerholt H, Steinbakk M (1986) Influence of ampicillin, clindamycin, and metronidazole on faecal excretion of short-chain fatty acids in healthy subjects. Scand J Gastronenterol 21: 621–628CrossRefGoogle Scholar
  27. Hospital Infection Control Practices Advisory Committee (HICPAC) (1995) Recommendations for preventing the spread of vancomycin resistance. Infect Control Hospital Epidemiol 16: 105–113Google Scholar
  28. Ings RM, McFadzean JA, Ormerod WE (1975) The fate of metronidazole and its implications in che-motherapy. Xenohiotica 5: 223–235CrossRefGoogle Scholar
  29. Jang SS, Hansen LM, Breher JE, Riley DA, Magdesian KG, Tang YJ, Silva J Jr (1997) Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant strains. Clin Infect Dis 25 (Suppl 2): S266–277PubMedCrossRefGoogle Scholar
  30. Johnson S, Adelman!) A, Clabots CR, Peterson LR, Gerding DN (1989) Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 159: 340–343PubMedGoogle Scholar
  31. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN (1992) Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. Ann Intern Med 117: 297–302PubMedGoogle Scholar
  32. Keighley MR, Burdon DW, Arabi Y, Alexander-Williams J, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GAG (1978) Randomized controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 2: 1667–1669PubMedCrossRefGoogle Scholar
  33. Kleinfeld DI, Sharpe RJ, Donta ST (1988) Parenteral therapy for antibiotic-associated pseudomembranous colitis. J Infect Dis 157: 389PubMedCrossRefGoogle Scholar
  34. Leung DYM, Kelly CP. Boguniewicz M, Polhoulakis C. LaMont JT, Flores A (1991) “treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by (’/, svri(/irtmt docile toxin. 1 Pediatr 118: 633 637Google Scholar
  35. Levetl PN (1991) Time-dependent killing of (Yosvridiumt (/i//ici/c by metromdazolc and vamwl1ncln. J Antimicroh Cheinolher 27: 55 62Google Scholar
  36. Liacouras CA, Piccoli DA (1996) Whole-bowel irrigation its an adjunct to the treatment of chronic. relapsing Clostridium (Wile colitis. J Clin Gastroenterol 22:186 IS9Google Scholar
  37. Lippsett PA, Samantaray DK, Tani ML, Bartlett JG, I.illemoe KD (1994) Pscudol11 I I) anous colitis: A surgical disease? Surgery 116: 491 496Google Scholar
  38. Lowenkron SL’, Waxncr J, Khullar P, Ilowite.IS. Niederntan MS. Fein AM (1996) C/ostrìu/nmm (lillirif infection as a cause of severe sepsis. Intensive Care Mcd 22: 990Google Scholar
  39. McFarland LV, Surawicz CM. Greenberg RN, Fekety R, Limy): (ì, Moyer IU, Melcher S.A. Bowen K lì. Cox JI.. Noorani Z. Harrington (ì, Rubin M. Greenwald D (1994) Randomized placebo-controlled trial of Sacrhuromn’res hotdarrlii in combination with standard antibiotics for Clostridium (/i/licih’ disease..1 Amer Med Assoc 271: 1913 1918CrossRefGoogle Scholar
  40. Mogg GAG, George RI I, Youngs D, Johnson M. Thompson II. Burden I)W. Kcighley MRB (1982) Randomized controlled trial of colestipol in antibiotic-associated colitis. Brit J Sure 69: 137 139Google Scholar
  41. Moncino MD, Falletta JM (1992) Multiple relapses of Hoy/rid/um (/ fficih-associated diarrhea in a cancer patient: successful control with long-term cholcslyramine therapy. Am J Pediatr- Hematol Oncol 14: 361 364Google Scholar
  42. Morris.113, Zollinger RM, Stellato “CA (19911) Role of surgery in antibiotic-induced pseudomembranous colitis. Am J Surg 160: 535–539Google Scholar
  43. Novak L, Lee.1G, Seckman CE. Philips JP, DiSanto AR (1976) Unfavorable effect of atropinediphenoxylate (Lomotil) therapy in Iincomyein-caused diarrhea..1 Amer Mad Assoc 235: 1451 1451Google Scholar
  44. Olson MM, Shanholtzer M t, Lee J f Jr, (ìcrding DN (1994) Ten years of prospective C7o.str6/ium (1ì///a11 associated disease surveillance and treatment at the Minneapolis VA Medical Center. 1982 1991. Infect Cont Ilosp I:pidemiol 15: 371–381Google Scholar
  45. O’Neill GL, Beaman MII. Riley TV (1991) Relapse versus reinfection with (loiii’6limmt r/i//iri/r. lIpidemiol Infect 107:627 (i35Google Scholar
  46. Purvis Y, Hautefcuille l’, Hecht Y, Le Ilouelleur.1. Compel II (1992) Surgical treatment of toxic mega-colon complicating pseudomembranous colitis. Apropos of a ease, review of the literature. Ann Chit-46: 453 457Google Scholar
  47. Peterson LR. Gercling DN (1990) Antimicrobial agents in Clostridium di//iri/c-associated intestinal disease. In: !Zambian’ J-C’, Ducluzeau R (eds) Clostridium di//ici/r-associated intestinal diseases. Springer-Verlag, Paris, pp I 1 S- 127Google Scholar
  48. Pruksananonda P, Powell KR (1989) Multiple relapses of C/ostridiumt di%/ici/e-associated diarrhea responding to an extended course of cholestyr,nine. Pediatr Infect Dis J 8: 175 178Google Scholar
  49. Sanchez JI., Gerding DN, Olson MM, Johnson S (1999) Metronidazole susceptibility in Clrnariditum did/kite isolates recovered from cases of C. difficile-associated disease treatment failures and successes. Anaerobe (in press)Google Scholar
  50. Seal I), Borriello SP. Barclay F. Welch A. Piper M, Bonnycastle M (1987) Treatment of relapsing Clostridium di%/iri/c cliarrheu by administration of a non-toxigenic strain. Eur.1 (’lin Microhiol 6: 51–53Google Scholar
  51. Silva J Jr (1989) Update on pseudomembranous colitis. West.1 Med 15I’644–648Google Scholar
  52. Silva.1 Jr. Batts 1)11, Fekety R, Ploull’e JE. Rifkin 01), Baird 1 (1981) Treatment of Clostridium colitis and diarrhea with vancomyein. Ani J Med 71: 815–822Google Scholar
  53. Surawicz (’M, McFarland I.V, Elmer G. Chin J (1989) Treatment of recurrent C/osmidiumt di//irì/r colitis with vancomyein and.S’arrharomn’crs houlm’dii. Ant J (ìastroenterol 54:1.’-85 1287Google Scholar
  54. Swedish C’DAD Study Group (1994) Treatment of CluStrirlium di//iri/r associated diarrhea and colitis With an oral preparation of teicoplanin: a dose finding study. Stand J Infect Dis 26309–316Google Scholar
  55. Teasley DG. (ìcrding ON, Olson MM, Peterson LR, Gebhard RI., Schwartz ML, Lee MI. Jr (1983) Prospective randomized trial of nnetronidazole versus vancomyein for Hoy/rid/um di/Jill/e-associ:ucd diarrhea and colitis. Lancet ü: 1043–1046Google Scholar
  56. Tedesco I J, Gordon D, Fortson WC (1985) Approach to patients with multiple relapses o1 antibiotic-associated pseudomembranous colitis. Am J Gastroenterul 80: 867–868Google Scholar
  57. Triadafìlopoulos (ì, Hailstone AL (1991) Acute abdomen as the (frst presentation of pseudomembranous colitis. Gastroenterology 101: 685–691Google Scholar
  58. Trudel JL. Deschenes M, Masri nd S, Barkun AN (1995) Toxic uncgaculuin complicating pseudomembranous enteroculitis. Dis Colon Rectum 38:1033–1038Google Scholar
  59. Tvede M, Rusk-Madsen.1 (1989) Bacteriothcrapy for chronic relapsing Clostridium difficilc diarrhea in six patients. Lancet i: 1156 1160Google Scholar
  60. Warny M, Denie C, Dclmce M, Lefebvre C (1995) Gamma globulin administration in relapsing Clostridium ( Wile-induced pseudomemhranous colitis with a defective antibody response to toxin A. Acta Clin BeIg 50: 36–39Google Scholar
  61. Wenisch C. Parschalk B, Hascnhundl M, Hirsch) AM, Graninger W (1996) Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium di//ici/c-associated diarrhea. Clin Infect Dis 22: 813 818Google Scholar
  62. Wilcox MH (1998) Treatment of Clostridium dif/icile infection,I Antimicrob Chemother 41(Suppl C): 41 46Google Scholar
  63. Wilcox M H, Fawley WN, Settle CD, Davidson A (1998) Recurrence of symptoms in Clostridium difficile infection -relapse or reinfection? J I losp Infect 38: 93–100CrossRefGoogle Scholar
  64. Wilcox MH, Howe R (1995) Diarrhoea caused by Clostridium r/it/ici/c: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother 36: 673 679Google Scholar
  65. Young GP, Ward PB, Bayley N, Gordon D, Higgins G, Trapani.IA, McDonald, MI, Lahrooy J, I lecke R (1985) Antibiotic-associated colitis due to C/ostridimn difficdc: Double-blind comparison of vancomycin with bacitracin. Gastroentcrol 89: 1038–1045Google Scholar
  66. Zimmerman MJ, Bak A, Sutherland LR (1997) Review article: Treatment of Clostridium dif/kite infection. Aliment Pharmacol Ther 11: 1003–1012PubMedCrossRefGoogle Scholar
  67. Zuckerman E, Kane! G, Ila C. Kahn J, Gottesman B-S, Korula J (1997) Low albumin gradient ascites complicating severe pseudomembranous colitis. Gastroenterology 112: 991–994Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • D. N. Gerding
    • 1
  1. 1.Department of Medicine, Medical Service, Veterans Affairs Chicago Healthcare System — Lakeside DivisionNorthwestern University Medical SchoolChicagoUSA

Personalised recommendations